AtaiBeckley Inc.
ATAIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. With a market capitalization of $2.70B, it sits in mid-cap territory. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder.
Market Cap
$2.70B
Beta
1.55
P/E (TTM)
—
P/E (Fwd)
-14.86
EPS (TTM)
$-2.79
EPS (Fwd)
$-0.49
ROE
-417.2%
ROA
-39.0%
Cash
$225.8M
Total Debt
$4.3M
Free CF
-$74.7M
52W Change
56.6%
Annual Financials
Cash vs Debt
Where ATAI stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, ATAI finished 56.24% above its 150-day moving average ($4.73) and 62.06% above its 200-day moving average ($4.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ATAI overbought or oversold?
At the August 27, 2026 close, ATAI's RSI(14) was 70.6, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $225.8M in cash comfortably exceeding the $4.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$74.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -417.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $233K (2022) to $4.1M (2025), reflecting a 1655% increase over the period.
AtaiBeckley Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, ATAI has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence AtaiBeckley Inc.'s trajectory.